Lysosomal Disorders

The CGTLive Lysosomal Disorders specialty topic page contains video interviews with key opinion leaders discussing the most relevant FDA actions, clinical guideline updates, and clinical trial findings related to cell therapies, gene therapies, and engineered and regenerative medicines developed for Lysosomal storage diseases. It also houses the most up-to-date clinical news coverage in the field of gene and cell therapy for diseases related to lysosomal storage and dysfunction.

Latest News

CGTLive®’s Weekly Rewind
CGTLive®’s Weekly Rewind – December 6, 2024

December 6th 2024

Review top news and interview highlights from the week ending December 6, 2024.

Around the Helix: Cell and Gene Therapy Company Updates – December 4, 2024
Around the Helix: Cell and Gene Therapy Company Updates – December 4, 2024

December 4th 2024

SC291 CAR T-Cell Therapy Fast Tracked for Relapsed/Refractory SLE
SC291 CAR T-Cell Therapy Fast Tracked for Relapsed/Refractory SLE

December 4th 2024

CGTLive®’s Weekly Rewind
CGTLive®’s Weekly Rewind – November 29, 2024

November 29th 2024

Around the Helix: Cell and Gene Therapy Company Updates – November 27, 2024
Around the Helix: Cell and Gene Therapy Company Updates – November 27, 2024

November 27th 2024

Video Interviews
Latest CME Events & Activities

Navigating the Next Wave in BTK Inhibition Strategies: Maximizing Clinical Benefit in CLL and MCL, What’s Next...

December 14, 2024

Register Now!

Oncology Town Hall™: Primary Investigators Present Key Abstracts in CLL from San Diego

View More

Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!

View More

Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!

View More

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL

View More

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL

View More

Real-World Applications of Asparaginase Formulations in ALL and LBL From Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care

View More

How Do We Treat GVHD Today…And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease

View More

Putting Your Stamp on the Next Generation of Care in CML — Improving Outcomes from Frontline to R/R Treatment Settings

View More

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

View More

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

View More

Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead

View More

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

View More

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

View More

29th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

February 27 - March 2, 2025

Register Now!

Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions

View More

ACCC 50th Annual Meeting Pre-Session: Clinical Updates from San Diego on Hematologic Malignancies

View More

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

View More

28th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

View More

9th Annual Live Medical Crossfire®: Hematologic Malignancies

July 26, 2025

Register Now!

More News

© 2024 MJH Life Sciences

All rights reserved.